Emergent BioSolutions, Inc. (EBS)
5.05
-0.10
(-1.94%)
USD |
NYSE |
Nov 20, 16:00
5.07
+0.02
(+0.40%)
Pre-Market: 20:00
Emergent BioSolutions EPS Diluted (Quarterly) : -0.6374 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.6374 |
| June 30, 2026 | -3.492 |
| March 31, 2026 | 0.0743 |
| December 31, 2025 | -1.042 |
| September 30, 2025 | 0.9062 |
| June 30, 2025 | -0.2214 |
| March 31, 2025 | 1.187 |
| December 31, 2024 | -0.5775 |
| September 30, 2024 | 2.065 |
| June 30, 2024 | -5.382 |
| March 31, 2024 | 0.1724 |
| December 31, 2023 | -0.9538 |
| September 30, 2023 | -5.085 |
| June 30, 2023 | -5.154 |
| March 31, 2023 | -3.709 |
| December 31, 2022 | -1.764 |
| September 30, 2022 | -1.746 |
| June 30, 2022 | -1.128 |
| March 31, 2022 | -0.073 |
| December 31, 2021 | 3.499 |
| September 30, 2021 | -0.6089 |
| June 30, 2021 | 0.0852 |
| March 31, 2021 | 1.279 |
| December 31, 2020 | 3.421 |
| September 30, 2020 | 0.7274 |
| Date | Value |
|---|---|
| June 30, 2020 | 1.733 |
| March 31, 2020 | -0.2404 |
| December 31, 2019 | 0.8916 |
| September 30, 2019 | 0.826 |
| June 30, 2019 | -0.1845 |
| March 31, 2019 | -0.5078 |
| December 31, 2018 | -0.0668 |
| September 30, 2018 | 0.4068 |
| June 30, 2018 | 0.9801 |
| March 31, 2018 | -0.099 |
| December 31, 2017 | 0.67 |
| September 30, 2017 | 0.68 |
| June 30, 2017 | 0.11 |
| March 31, 2017 | 0.23 |
| December 31, 2016 | 0.7792 |
| September 30, 2016 | 0.45 |
| June 30, 2016 | -0.27 |
| March 31, 2016 | 0.10 |
| December 31, 2015 | 0.72 |
| September 30, 2015 | 0.79 |
| June 30, 2015 | 0.32 |
| March 31, 2015 | -0.57 |
| December 31, 2014 | 0.66 |
| September 30, 2014 | 0.4689 |
| June 30, 2014 | 0.13 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 2.561 |
| Arcturus Therapeutics Holdings, Inc. | -0.2607 |
| Travere Therapeutics, Inc. | -0.645 |
| Syndax Pharmaceuticals, Inc. | -0.5505 |
| Novavax, Inc. | -0.1902 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -32.70M |
| Revenue (Quarterly) | 110.00M |
| Total Expenses (Quarterly) | 142.70M |
| Enterprise Value | 595.86M |
| Gross Profit Margin (Quarterly) | 18.09% |
| Profit Margin (Quarterly) | -29.73% |
| Earnings Yield | -100.9% |
| Operating Earnings Yield | 12.00% |
| Normalized Earnings Yield | -40.00 |